ID
40934
Description
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01698918
Link
https://clinicaltrials.gov/show/NCT01698918
Keywords
Versions (1)
- 6/7/20 6/7/20 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
June 7, 2020
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Hormone Receptor Positive Breast Cancer NCT01698918
Eligibility Hormone Receptor Positive Breast Cancer NCT01698918
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Non-Measurable Lesion | Exception Secondary malignant neoplasm of bone | Pleural effusion | Ascites
Data type
boolean
Alias
- UMLS CUI [1]
- C1334988
- UMLS CUI [2,1]
- C1705847
- UMLS CUI [2,2]
- C0153690
- UMLS CUI [3]
- C0032227
- UMLS CUI [4]
- C0003962
Description
Prior Hormone Therapy Secondary malignant neoplasm of female breast | Systemic therapy Secondary malignant neoplasm of female breast
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1514460
- UMLS CUI [1,2]
- C0346993
- UMLS CUI [2,1]
- C1515119
- UMLS CUI [2,2]
- C0346993
Description
Hormone Therapy Neoadjuvant allowed | Prior adjuvant endocrine therapy allowed | NSAID Neoadjuvant Treatment completed | NSAID Adjuvant Treatment completed | Letrozole Treatment completed | Anastrozole Treatment completed
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0279025
- UMLS CUI [1,2]
- C0600558
- UMLS CUI [1,3]
- C0683607
- UMLS CUI [2,1]
- C0281266
- UMLS CUI [2,2]
- C0683607
- UMLS CUI [3,1]
- C0003211
- UMLS CUI [3,2]
- C0600558
- UMLS CUI [3,3]
- C0580352
- UMLS CUI [4,1]
- C0003211
- UMLS CUI [4,2]
- C1522673
- UMLS CUI [4,3]
- C0580352
- UMLS CUI [5,1]
- C0246421
- UMLS CUI [5,2]
- C0580352
- UMLS CUI [6,1]
- C0290883
- UMLS CUI [6,2]
- C0580352
Description
mTOR Inhibitors
Data type
boolean
Alias
- UMLS CUI [1]
- C1515672
Description
Hypersensitivity mTOR Inhibitors | Hypersensitivity Sirolimus
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C1515672
- UMLS CUI [2,1]
- C0020517
- UMLS CUI [2,2]
- C0072980
Description
Eligibility Criteria Study Protocol
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348563
Similar models
Eligibility Hormone Receptor Positive Breast Cancer NCT01698918
- StudyEvent: Eligibility
C1519810 (UMLS CUI [1,2])
C3495949 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
C0346993 (UMLS CUI [3,1])
C1548788 (UMLS CUI [3,2])
C1511562 (UMLS CUI [3,3])
C3495949 (UMLS CUI [4,1])
C1548788 (UMLS CUI [4,2])
C1511562 (UMLS CUI [4,3])
C0346993 (UMLS CUI [5,1])
C1548788 (UMLS CUI [5,2])
C1522449 (UMLS CUI [5,3])
C1276305 (UMLS CUI [5,4])
C3495949 (UMLS CUI [6,1])
C1548788 (UMLS CUI [6,2])
C1522449 (UMLS CUI [6,3])
C1276305 (UMLS CUI [6,4])
C0279754 (UMLS CUI [1,2])
C2348908 (UMLS CUI [1,3])
C0332197 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
C0032227 (UMLS CUI [3])
C0003962 (UMLS CUI [4])
C0346993 (UMLS CUI [1,2])
C1515119 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
C0600558 (UMLS CUI [1,2])
C0683607 (UMLS CUI [1,3])
C0281266 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0003211 (UMLS CUI [3,1])
C0600558 (UMLS CUI [3,2])
C0580352 (UMLS CUI [3,3])
C0003211 (UMLS CUI [4,1])
C1522673 (UMLS CUI [4,2])
C0580352 (UMLS CUI [4,3])
C0246421 (UMLS CUI [5,1])
C0580352 (UMLS CUI [5,2])
C0290883 (UMLS CUI [6,1])
C0580352 (UMLS CUI [6,2])
C1515672 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0072980 (UMLS CUI [2,2])
C2348563 (UMLS CUI [1,2])